NAD+ vs Teriparatide
A side-by-side research comparison of NAD+ and Teriparatide across mechanism, dosing, half-life, benefits, side effects and research status.
Comparison table
| Attribute | NAD+ | Teriparatide |
|---|---|---|
| Full name | Nicotinamide Adenine Dinucleotide (NAD+ / NMN / NR) | Teriparatide (PTH 1-34) |
| Category | Anti-Aging | Anti-Aging |
| Status | Research compound | FDA-approved drug (prescription) |
| Mechanism | NAD+ serves as cofactor for sirtuins (SIRT1-7), PARPs (DNA repair), and CD38. Declining NAD+ impairs mitochondrial function and epigenetic maintenance. Restoration reactivates longevity pathways. | Intermittent dosing of PTH 1-34 preferentially stimulates osteoblasts (bone-building cells) over osteoclasts, increasing bone formation, trabecular bone mass, and bone strength. |
| Molecular weight | 663.4 Da | 4117.8 Da |
| Half-life | 1-4 hours (IV), 4-8h (oral precursors) | ~1 hour (subcutaneous) |
| Bioavailability | 100% (IV), variable (oral 5-30%) | ~95% subcutaneous |
| Typical dose | 250-500mg IV or 500-1000mg NMN oral | 20 mcg once daily (medical) |
| Frequency | Weekly (IV) or Daily (oral) | Once daily |
| Route | IV infusion or Oral (precursors) | Subcutaneous injection |
NAD+ reported benefits
- Restored cellular energy
- Enhanced DNA repair
- Sirtuin activation
- Improved mitochondrial function
- Cognitive clarity
- Anti-aging
Teriparatide reported benefits
- Actively builds new bone
- Increases bone mineral density
- Reduces fracture risk (medical)
- Supports bone healing
Related comparisons
Research and educational reference only. Not medical advice.